Deliver logo
Previous Sponsor
Cytiva is a global provider of technologies and services that help advance and accelerate the development and manufacture of therapeutics. Previously GE Healthcare Life Sciences, Cytiva’s diverse portfolio includes well-recognized brands such as ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Whatman and Xcellerex. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the delivery of transformative medicines to patients. Visit cytiva.com for more.
作为全球生命科学领域的技术和服务供应商,Cytiva致力于推动未见技术,加速非凡疗法,从而实现创新疗法的可及,变革人类健康的未来。在GE医疗生命科学事业部奠定的坚实基础之上,Cytiva(思拓凡)拥有多样的产品组合,包括ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Whatman和Xcellerex等知名产品品牌。Cytiva全面助力客户提升科学研究与工业化生产流程中的速度、效率与能力,赋能创新型药物的发展和生产,惠及全球患者。
更多信息,敬请访问: www.cytiva.com
智荟专线:400-810-9118
官微订阅号:Cytiva
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, and cell culture. Almost 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has more than 2,000 employees in 28 countries – all dedicated to helping researchers and clinicians make a greater impact on science and health.
As a trusted tool provider for clinicians and industry, from large to small, CliniMACS® Systems provide technologies and instruments to the clinic. From immuno-oncology, regenerative medicine, to graft engineering, you’ll find comprehensive solutions for numerous clinical settings.
Using CliniMACS Systems, cell products have been manufactured for all stages of clinical development - from discovery to IND submission and ongoing clinical trials. We are committed to supporting investigators with solutions that enable the clinical translation and practice of novel cell and gene therapies. This support includes products and services that extend the value beyond the device and consumables.
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.​​ Together with our customers, we unlock the potential of blood and cellular therapies to enable better lives
BIA Separations specializes in chromatographic purification of the most challenging biomolecules. The ability of a purification process to deal with big vulnerable molecules and stubborn impurities, for example, hcDNA, is a distinctive advantage. BIA’s downstream platforms are based on unique monolithic chromatographic media, namely, CIM® monolithic columns, distinguished for their flow independent performance, resulting in fast separation, concentration, purification and analytics. Elaborate column design reduces shear stress that vulnerable molecules are subjected to, thus significantly increases final recovery. Cutting-edge applications focus on downstream processing of exosomes, viruses (AAV, Influenza, etc.), plasmid DNA, bacteriophages and mRNA. We provide products that range from small analytical columns to large industrial prep-scale columns (including cGMP and disposable units in IEX, HIC, affinity and customized formats). As such, our products are used in research, laboratory, pilot and industrial production stages and are extremely simple to use, with no packing of columns needed.
The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With over 180 experts focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or visit https://ct.catapult.org.uk.
Sartorius Stedim Biotech is a leading international provider of integrated solutions for the biopharmaceutical industry. With our extensive portfolio of products, technologies and services, we cover wide areas of the biopharmaceutical process chain, ranging from fermentation, cell cultivation, filtration and purification to media storage and transportation. In process filtration, fermentation and fluid management, our company holds leading positions in the markets it serves across the globe. Our single-use products that have meanwhile become established in nearly all process steps are playing an increasingly important role in the manufacture of biopharmaceuticals. As a result, we help our customers produce biological medications and vaccines safely and efficiently.
Beckman Coulter Life Sciences is dedicated to improving the health of people around the world. The company’s global leadership and world-class service and support delivers sophisticated instrument systems, reagents and services to life science researchers in academic and commercial laboratories, enabling new discoveries in biology-based research and development. A leader in centrifugation and flow cytometry, Beckman Coulter has long been an innovator in life sciences instruments and solutions used at the forefront of important areas of investigation, including genomics, proteomics and cellular research.
Marken is a wholly owned subsidiary of the UPS Healthcare division. With Polar Speed and Marken included, the UPS Healthcare division staffs 128 locations with 5500 employees worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 56 locations worldwide, while maintaining the leading position for Direct to Patient and Home Health care services, biological sample shipments and biological kit production. Marken’s dedicated 1300 staff members manage 85,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries. Additional services such as ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.
MaxCyte is a global cell-based medicines and life sciences company applying its proprietary cell engineering technology platform to deliver the advances of cell-based medicine to patients with high unmet medical needs in a broad range of conditions. MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical industry partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer. MaxCyte has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, and has more than 70 partnered program licenses in cell therapy including more than 35 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products.
For more information, visit www.maxcyte.com.
CellGenix is a leading global supplier of high quality raw materials for the expanding cell and gene therapy and regenerative medicine space. We develop, manufacture and market human cytokines and growth factors in preclinical and GMP quality along with GMP serum-free media for further manufacturing of ATMPs. Our products are used by academia and industry partners in clinical trials and commercial manufacturing throughout the world.
With 25 years of experience we are experts in the GMP manufacturing of raw materials for the cell and gene therapy space. As an ATMP developer and manufacturer we gained in-depth cell culture knowledge and superior regulatory expertise. With this unique background we understand the high requirements our customers face during product development and the regulatory approval process. By offering expert technical and regulatory support we can help simplify raw material qualification and validation efforts.
CellGenix is headquartered in Freiburg, Germany and operates a subsidiary near Boston in Portsmouth, USA.
凯莱英医药集团(天津)股份有限公司(股票代码:002821.SZ)是一家全球领先的CDMO公司,为全球新药提供高质量的研发、生产一站式服务。以加速新药上市,延长生命的质量为己任,依托持续技术创新,为国内外制药公司、生物技术公司提供药品全生命周期一站式CMC服务,加快新药开发及应用。
目前拥有全球8大研发生产基地,15家公司,近4000名员工。业务范围覆盖临床早期到商业化阶段,包括高级中间体,原料药,制剂等的研发和cGMP生产,以及临床研究服务。并通过战略合作与业务拓展,逐步构建起创新药一体化服务生态圈,做全球新药研发生产的合伙人。
Website:
杭州剂泰医药定位于人工智能驱动新药制剂开发,由美国工程学院院士及多位麻省理工(MIT)科学家领衔,将高通量制剂平台及人工智能计算等技术集合,为药企提供快速、精确、智能化制剂研发。愿景是通过提高药物生物可利用度、稳定性等方式提升大小分子药物的成药性质,通过延长体内半衰期以及新的载体系统等改善药物释放控制率,得到更好的药效效果,通过新递送系统、新剂型实现靶向输送,设计具有临床差异化的制剂新药,致力于成为新药递送的设计师。
江苏集萃药康生物科技有限公司是一家专业从事基因修饰模型与药物筛选技术研发的高科技生物技术企业,具有领先的疾病模型研发创制能力和基因工程改造小鼠模型创制中心。2018年公司旗下“人源化模型与药物筛选创新技术研究院”被江苏省产业技术研究院吸纳为“专业研究院”,成为该领域重点扶持架设产业链、国际化发展的新型研发机构。公司旨在为全球的合作伙伴提供模型创制、饲养繁育、小鼠销售、表型分析、功能药效等一站式创新技术及资源服务。利用领先的基因编辑技术,集萃药康已建立多个可用于药物评价的小鼠模型及应用平台,如基因人源化模型、免疫重建模型等。
北京艾德摩生物技术有限公司(Beijing IDMO Co., Ltd.)致力于肿瘤转化医学研究及癌症个性化治疗。通过使用自主研发的人源肿瘤异种移植模型(patient derived xenograft model,PDX),针对不同的癌症患者筛选适合的治疗药物,为医生提供精确的临床用药指导,进而共同为患者提供具有针对性和高效性的个性化治疗方案。同时依托自研的肿瘤免疫评价平台,帮助药企针对治疗性单抗、双抗、细胞疗法、肿瘤疫苗等肿瘤免疫类疗法,开展药物药效和安全性评价,提高研发成功率、降低研发成本。
Scientists and doctors have limited knowledge of how different people respond to different treatments. Today, personalized medicine is moving us closer to more precise, predictable and powerful treatment. Founded in 2014, IDMO, the genome engineering specialist, is devoted to developing the highly physiologically relevant animal models, whose value in drug development is increasingly being demonstrated with the advancement of personalized therapies. Our growing understanding of genetics allows us to establish the very animal ‘patients’, then boost the ability of predicting drug effects in the individual patient.
上海亓上生物医学科技有限公司是由上海富朗特动物保健股份有限公司结合自身在动物营养、动物保健和生物医学方面的相关优势和资源,于2019年5月在上海周浦国际医学园区成立的一站式实验动物相关服务平台和创新型技术研发转化中心。我们以打造国际一流的动物实验平台和完善实验动物的标准化营养体系为目标,同时建立和发展高效、个性化的肿瘤实验动物模型和治疗方案、药物研发技术体系,推动转化医学的发展。
Shanghai Qishang Biomedical Technology Co., Ltd. was established in Shanghai Zhoupu International Medical Park in May 2019 by Shanghai Frontan Animal Health Co., Ltd., combining its own advantages and resources in animal nutrition, animal health and biomedicine. Qishang is a One-stop laboratory animal related service platform as well as an innovative technology transformation center. We aim to build a world-class animal experiment platform and improve the standardized nutrition system for experimental animals. At the same time, we are also dedicated to establish and develop efficient and personalized tumor experimental animal models and treatment plans, as well as a drug development technology system to promote the development of translational medicine.
南京海维医药科技有限公司是由江苏省双创人才、江苏省产业教授王立坤博士创办的企业。南京海维医药科技有限公司注册在南京经济开发区。从2018年投入运营以来,企业围绕加速药物开发流程进行布局,同步实现了技术创新和营收快速增长。在技术创新方面,南京海维是目前在亚太区唯一能够提供专业的药物超快速稳定性研究的实验室。业务方面,涵盖了新药早期开发的固相化学、分析检测、制剂开发等。  
自成立以来南京海维已经同阿斯利康、西安杨森、江苏恒瑞、和记黄埔、正大天晴等一流企业达成战略合作,解决重磅产品的稳定性、成药性等关键共性问题,极大加速了创新药的开发进程。
安捷伦科技公司(纽约证交所: A )是生命科学、诊断和应用化学市场领域的全球领导者。安捷伦现已进入独立运营的第二十年,一直致力于为提高生活质量提供敏锐洞察和创新经验。安捷伦的仪器、软件、服务、解决方案和专家能够为客户最具挑战性的难题提供更可靠的答案。2019财年,安捷伦的营业收入为51.6亿美元,全球员工数为 16300 人。
安捷伦科技1999年11月从惠普分拆,在纽交所上市并成为硅谷史上最大的IPO。安捷伦延续了两位创始人Bill和Dave于1939年在 Palo Alto的小车库里所创立的科技创新传统,凭借领先的技术及其它优势,安捷伦持续引领测试测量行业的发展,始终在全球测试测量领域名列前茅。
1985 年成立的中国惠普/安捷伦是中国第一家高科技合资企业。迄今为止,安捷伦在中国拥有将近1500名员工;在中国37个城市设有六家子公司和 14 个办事处,业务涉及产品研发及制造、市场推广、销售、和售后服务支持等。
从1939创立到2018年,安捷伦科技一直是全球领先的测试测量公司,为产业和科研提供应用广泛的创新解决方案。安捷伦的专业知识和深受信赖的合作能力,使得客户对我们提供的解决方案满怀信心。安捷伦公司不断推动科技进步,提升人们的生活品质。
面对客户,安捷伦将一如既往地提供全线的产品、服务、消耗品与软件,以及生命科学、诊断和应用领域的完整解决方案。安捷伦将集中资源为客户打造全球一流的实验室合作伙伴,协助您在所从事的领域与工作中创造一个更美好的世界。我们将继续专注于六大关键领域:食品、环境和法医、制药、诊断、化工与能源和科研。
乐威医药(江苏)股份有限公司创建于2005年,是专业从事创新医药产业化外包服务(CDMO)的高新技术企业。主要服务范围涵盖创新医药从实验室到产业化的工艺开发和转化的化学相关环节,包括临床前到上市药品的工艺研究、工艺开发、工艺优化、中试工艺和规模化生产的服务,也包括提供在开发过程中的报批服务(CMC)。2015年企业完成股份制改制,现有4个全资子公司:乐威医药(天津)有限公司、乐威医药(沧州)有限公司、北京乐威泰克医药技术有限公司,乐威医药(江苏)股份有限公司。
江苏欣诺科催化剂有限公司:
成立:2008年;
总部:江苏省苏州张家港市;
主营业务:金属配合物、配体;
员工:170+人;
研发团队:50名,7名博士、10+名硕士;
研发中心:苏州张家港市,4500平米;
工厂:2个,池州50亩在用,铜陵100亩在建(2021年投产);
欣诺科为全球超过600家企业提供服务,我们提供金属有机化合物的定制服务。
Sinocompound Catalysts Co., Ltd. was established in 2008 with headquarter in Zhangjiagang. We have achieved ISO 9001, ISO 18001, ISO 14001 certification. The company was evaluated as High-Tech enterprise in Jiangsu Province.
Sinocompound focuses on homo- and heterogeneous metal catalysts, ligands, high-purity electronic and custom synthesis service. Our R&D center located in Zhangjiagang headquarter, occupies 21,500 sq ft with an excellent team consists of several experienced ph. D chemists from renowned American research institutes. The factory with a space of 8.2 acres, is world-class equipped to guarantee scale-up production. With years of research, we have gained rich experience in organometallic
synthesis, purification and scale manufacture and successfully developed several series of metal catalysts. Our homogeneous catalyst products include complexes containing palladium, ruthenium, rhodium, iridium, gold, platinum, nickel, copper, zirconium, etc. Our ligands products are mainly based on phosphorus, nitrogen, oxygen chiral ligands. In 2013, we were authorized by MIT in manufacture of Buchwald ligands and catalysts. We also cooperate with Nanjing University to provide custom synthesis and catalyst screening service.
Our management team has industrial experience of over 10 years. We value most the original research, good management, and quality control, which are key to products’ quality, reasonable pricing and timely delivery.
Our products have been widely applied by over 800 customers from renowned pharmaceutical companies, research institutes and universities worldwide. We routinely collect feedback from clients to improve our products and services.
Johnson Matthey Pharmaceutical Services (Yantai) Co., Ltd is a 100% holding company of Johnson Matthey Group, and is a part of our Innovator business unit in Health Sector. Along with the JM global network in Pharma Services, Chiral Technology and API business, JM Yantai site has an established a strong team in R&D and management based on easily accessible raw material and sufficient talent pool which allow us to supply tailored technology, process R&D services, advanced intermediate and API production for high-end innovator pharmaceutical clients.
明捷医药是一家提供一站式的药物质量研究及生产放行解决方案的第三方技术服务公司。在南京药谷、上海张江药谷、上海国际医学园区分别设有独立的质量控制实验室,面积共5000多平方米。明捷医药参照cGMP和CNAS质量体系建立了支持药品注册申报及生产放行的一体化药物质量控制实验室,为客户提供符合全球药政法规的药物质量研究、基因毒杂质研究、包材相容性研究、元素杂质研究、生物药工艺残留物研究、原料药备案、注射剂一致性评价等多项技术服务。
公司秉承“专业、创新、合作、责任”的理念,不断加强能力建设、质量体系建设及人才队伍建设,以专业的技术团队和合规的质量体系为客户提供高效率、高质量、合规的技术服务,一起为医药事业和人类健康而努力。
Milestone Pharma is a third-party technical service company that provides one-stop solutions for drug quality research and product release testing services. Milestone Pharma has three independent quality control laboratories in Nanjing Medicine Valley, Shanghai Zhangjiang Medicine Valley and Shanghai International Medical Zone , covering a layout area of more than 5,000 square meters. Milestone Pharma has established an integrated drug quality control procedures to support drug registration application and drug product release in compliance with cGMP and CNAS quality systems. We provide technical services including drug quality study, genotoxic impurity study, packaging material compatibility study (extractables and leachables), elemental impurity study, biological drug process residue study, DMF filing, generic drug consistency evaluation in compliance with global drug regulations.
Adhering to the concept of "specialty, innovation, cooperation and responsibility", we continuously strengthen on the improvement of capability, quality system and talent teams. We aim to provide customers with efficient, high-quality and well-compliant technical services with professional technical teams and GMP quality system.The quality of human health and pharmaceutical industry, we care and endeavor!
HitGen is a rapidly growing biotech company with headquarters based in Chengdu, China, with a subsidiary in the USA. HitGen has established an industry-leading platform for early-stage drug discovery research centred on DNA encoded chemical libraries (DELs). HitGen’s DELs include encoded syntheses for hundreds of billions of novel, diverse, drug-like small molecule and macrocycle compounds. These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed and assembled with tractable chemistry based on proven results for identifying drug-like leads against biological targets from known and novel classes. HitGen is working with multiple pharmaceutical and biotech companies, foundations and research institutes in North America, Europe and Asia to discover and develop novel therapeutics of the future.
Healthgen Biotechnology Corp. (Healthgen Biotech) is a private company founded in 2006. We are focusing on developing, manufacturing and marketing a series of environmental friendly and safe products by using the State-of-the-Art platform called OryzHiExp, having high capacity to express proteins or small peptides in the rice grain.
Using the OryzHiExp platform, Healthgen Biotech maximizes the innovative animal-free product development opportunities for clients and partners. Its cost-effective expression capability made it as a breakthrough expression platform.Healthgen Biotech has achievements in developing and commercializing products, such as OsrHSA, OsrbFGF, OsrIGF-1, OsrEGF, OsrLF, OsrAAT.
Healthgen Biotech’s Quality Control System has been certified by ISO 9001: 2008 and ensures standardized process as well as qualified products. Our scale production facility is compliant with GMP. All products can be used as the cell culture media supplements, industrial biological reagents in bio-pharmaceuticals processing and life science researches.
As one of the world’s most renowned companies for contract development and manufacturing, we are recognized for our reliable, high-quality service, our global capacity, our innovative technology platforms, and our extensive experience. In 2019 we provided manufacturing services for more than 300 commercial molecules and supported the development of more than 700 pre-clinical and clinical molecules in small and large molecules as well as supporting the launch of pioneering autologous cell therapies.
Success for us is when you, as our partner, are fully satisfied. We continuously improve and innovate to meet your expectations and improve your chances of business success. Our broad capabilities span across biologics, small molecules, bioconjugates, and cell and gene therapies. We manage projects from pre-clinical stage through to commercialization, and our expertise covers both drug substance and drug product.
妙顺(上海)生物科技有限公司是一家提供原代细胞应用解决方案的高新技术企业,现有4条原代细胞产品线涵盖肿瘤免疫、肝脏系统、肿瘤原代、皮肤系统,为创新肿瘤免疫治疗领域、肝脏疾病领域、精准治疗药物开发领域提供细胞产品和技术服务。公司目前拥有符合GMP标准的生产厂房,具备完善的生产质量管理体系,对研发、采购、生产、质检、存储和运输等环节实行严格的全程监控,确保产品质量。
Milestone Biotechnologies is a biotechnology company based in Shanghai, designed to coordinate, manage and provide scientific services to researchers, biotechnological companies and pharmaceutical laboratories.
We offer quality services based on cell isolation and cell solutions for in vitro and in vivo testing models addressed to the research community.
Our aim is to improve the availability of primary cells in different research markets while working to extend the utility and reproducibility of cellular tools and data.
Polyplus-transfection ® SA is a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics. Located close to the University of Strasbourg in France, Polyplus-transfection® applies it’s 17+ year expertise to the development of novel transfection solutions for mammalian cells. We provide reagents for high yield transient protein and antibody production in CHO and HEK-293 cells, as well as for viral vector production for Gene and Cell Therapy (PEIpro product range). Our products meet the quality requirements for use in bioprocesses up to GMP grade.
Charles River Laboratories, Inc. is a leading contract research service provider. We help accelerate drug development by supporting our clients’ research every step of the way. Microbial Solutions is one of the business segments of Charles River. We’ve purposely built our portfolio to bring you progressive products and services that deliver accurate, relevant, and reliable data to fuel confident decisions on product quality and contamination control. We lead the market with products and services that meet the diverse needs of the pharmaceutical, home, beauty, dairy, beverage, and food industries. Our unique combination of Endosafe® endotoxin testing, Celsis® rapid microbial detection, and Accugenix® microbial identification and strain typing keeps your manufacturing operations running efficiently and smoothly, lowers your cost to manufacture, and protects your reputation.
保诺科技是一家全球领先的新药研发CRO,自2005年成立以来,致力于为国内外的各保诺科技是一家全球领先的新药研发CRDMO公司,已经与包括全球十大跨国公司在内的800余家国内外著名制药公司以及Biotech建立起紧密、长期的合作关系。BioDuro自2005年成立至今,已经在美国圣地亚哥,中国北京、上海建立起三个高水平创新药物研究开发中心,而即将运营的江苏无锡研发中心将是BioDuro在全球最大的研发中心。BioDuro将在未来2年内发展成为拥有超过3000名科学家团队的全球著名CRDMO公司。保诺科技依托更加强大的全球化无缝运营的优势,一流的实验及生产设施,强大的科研团队以及精益求精的企业精神,为客户提供高水准的一体化临床前药物研发服务。大药企,生物医药公司提供从候选化合物的设计、合成到靶点验证、体内、外药效评价、作用机制研究,药代动力学分析,制剂以及临床样本生产的一站式新药研发服务。保诺科技在大小分子发现、研发和放大领域具备深厚的专业治疗背景,加之独有的技术平台,能提高不溶性化合物的生物利用度。公司总部位于美国加州的圣地亚哥,在中国的北京、上海和无锡3地均设有研发中心。保诺科技依托其全球化无缝运营的优势,凭借自身一流的实验设施,强大的科研团队以及精益求精的企业精神为客户提供了高水准的一体化临床前药物研发服务。
阿尔索斯(广州)咨询服务有限公司(AlsosTalent),是一家服务于医疗健康及生命科学产业,提供高管寻访招聘咨询服务机构。秉承“客户,为人才,为患者,为员工”的坚定目标,用专业的能力,真诚的服务、踏实的作风帮助药企解决核心资源即人才资源,以此推动生命科学行业发展。 Alsos总部设在中国,在美国新泽西/凤凰城等地兼设海外分支机构。 多年的行业深耕和精准交付,Alsos已经与数家全球顶尖的医药/医疗企业、CRO/CMO公司及国内领先的制药公司达成合作协议,协助其高管寻访并包括引进海外中高端人才。
We are a talent acquisition company committed to promoting Pharmaceuticals & Life Science industry by offering professional services to our clients with capacity, integrity, decency and passion. Our mission is to contribute to the development of the Pharmaceuticals & Life Science industry and the growth of our clients with believing in “For Clients, For Talents, For Patients, For Employers” as our principal.
We are expert in senior executives searching and recruiting. With years of experience in talent acquisition in Pharmaceuticals & Life Science industry, we successfully accomplished our clients’ talent plans like executives recruiting, senior management team building and overseas talent introduction etc.. We currently have deep cooperation with many outstanding companies including global/ local pharmaceuticals, biotech, CRO and CMO companies, based upon our high service quality promising and continuous projects delivering. Now, with headquarter in China, we have professional consultant teams in Guangzhou, Beijing, New Jersey and Phoenix.
Syneos Health™ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.
普瑞金——成立于2012年,是国家中小企业发展基金和中国科学院投资的高新技术企业。公司深耕于CAR-T细胞药物领域,拥有一支学术背景深厚、实践经验丰富的科研及产业化团队,分别在北京和深圳建有研发平台、CAR-T细胞药物CDMO平台。与国家上海新药安全评价研究中心达成战略合作,参与起草中检院2018年6月发布的《CART细胞质量控制检测研究及非临床评价考虑要点》。 普瑞金已实现多个CAR-T细胞药物的IND申报,现已打造全面符合IND申报标准的质粒、病毒、CAR-T细胞制备的全流程工艺及质量控制体系,使产品开发周期可控、产业化生产成本极具优势。
博志研新作为一家以改良型新药、创新药、高端制剂为核心的药物研发和生产服务(CRO/CDMO)企业,致力于打造国际化,前沿化的医药研发和创新平台。不仅在肿瘤、心血管、免疫、神经和精神等领域具有丰富的开发经验,在高端制剂技术(口服缓控释、口服固体增溶、长效注射液、液体与半固体等)方向上也具有丰富的专业经验和创新技术优势。
发展历程
2012年,上海博志研新药物技术有限公司成立,开展从事药物发现,原料药及中间体研发,高端制剂研发等一系列研发服务。
2014年,第一个临床批件(奥拉西坦注射液)和第一个生产批件(乐卡地平原料药)获得批准。
2016年,收购临床CRO-成都润泽医药科技开发有限公司。国家高新技术企业认定。
2017年,中国研发品牌20强
2018年,业务能力提升,研发管线进一步丰富。
2019年,上海,南京,成都三地新研发中心投入运营。
2020年,新建上海临港研发中心及中试基地。中国医药工业百强(CRO/CDMO))20强
核心优势
1、经验丰富的国际化研发团队
十多年的研发业务造就了博志研新完备而成熟的业务团队,主要研发及管理人员由江苏省十大青年科技领军人才及上海医工院、上海药物所、上海有机所、美国威斯康星大学、中国药科大学、南开大学和华东理工大学等经验丰富的高端人才组成。
2、一流的研发设备和研发场地
精良的仪器设备:公司投入了大量的资金配备先进的设备和仪器,拥有合成、分析、制剂、临床等研发和中试相配套的仪器设备百余台(套),满足药物研发项目的需要,确保项目高质高效进行。
3、海内外专家顾问资源
公司与海内外审评专家和高效建立了广泛的合作关系,拥有稳定的药学和临床专家团队,为药物全流程服务提供全面的技术指导。
4、严格的质量管理体系
2017年通过ISO9001质量管理体系认证,并通过2018年的监督审核; 公司400多个质量管理体系文件及SOP,确保系统性和规范性; 按注册及GMP要求,建立研发QA,对项目原始记录、项目注册资料、研发现场、数据管理的合规性进行检查;
质管部门对关键供应商进行现场审计,内部进行内部审核、管理审评、偏差管理、CAPA等,使体系持续改进。
5、创新的知识产权策略
2018年博志研新被评为“上海市专利工作试点企业”。已经授权的发明专利41项,在申请中的发明专利31项,国际专利1项。
在研发过程中,专利人员定期与研发人员沟通,一旦出现新的产品或技术及时进行专利布局和专利保护,确保每个项目都有专利进行保护,重点项目需要有专利群进行保护,最大程度的发挥专利对于创新技术的保驾护航作用。
特色平台:
一、制剂技术平台
1、缓释技术
2、控释技术
3、难溶性药物增溶技术
4、微丸释药技术
5、固体分散技术
6、空腔分散/崩解技术
7、注射溶液/吸入溶液技术
8、软膏/凝胶外用制剂技术
9、长效缓释混悬技术
二、合成研发能力:
规模化大生产合成工艺技术优化和创新,在不对称催化、酶催化、连续流反应技术、光化学反应技术、绿色化学反应技术、晶型筛选及稳定性研究等技术方面经验丰富。尤其擅长头孢与青霉素抗生素合成技术、糖合成技术、多肽合成技术、前列腺素合成技术。在抗肿瘤、抗病毒、抗糖尿病等多个领域经验丰富。
三、分析技术平台:
1、原料药质量研究
2、常规注射剂、口服固体制剂质量研究
3、缓控缓制剂质量研究
4、手性药物分析方法开发及验证
5、基因毒性杂质分析方法开发及验证
6、元素杂质分析方法开发及验证
7、药保持相容性研究
8、符合现考要求的质量管理体系
Website: www.porton.cn
Porton Pharma Solutions Ltd. (former name: Porton Fine Chemicals Ltd) founded in 2005, is a top-tier CDMO, providing services to the global pharmaceutical industry with intergraded research, development and manufacturing of custom drug intermediates and APIs.
We operate three Process R&D Centers, and three Manufacturing Sites across China, and leading US based CRO J-Star with expertise in GMP/GLP synthesis, Crystallization research and High potent handling etc.
Supported by >1,700 customer-centric employees, cutting-edge Process R&D Centers, USFDA and PMDA-inspected cGMP production sites and marketing offices located across China, North America and Europe, Porton helps its customers more efficiently deliver improved health outcomes to their patients through chemical process innovation, rapid scale-up and high-quality, cost-effective manufacture of APIs and/or drug intermediates.
Ask Us How We Can Help You @ www.porton.cn
Founded in 2004, Sundia MediTech Company Ltd. is a leading China-based CRO providing a broad range of high-quality, cost effective drug discovery and development services. Capitalizing on its broad service offerings, experienced scientists and advanced research facilities and equipment, Sundia helps its customers discover and develop novel drug candidates efficiently. Sundia currently provides services to over 160 customers globally, including a vast majority of the top 20 pharmaceutical and biotechnology companies in the world, as well as fast-growing biotechnology and specialty pharmaceutical companies and renowned academic and research institutions. Sundia currently boasts an experienced and strong R&D tem, comprised of over 700 employees, of over 70% have post-graduate degrees and an average of 15 years of relevant industry experience. The Company conducts its laboratory and development activities in three primary facilities in China: a) Shanghai Zhangjiang Hi-Tech Park; b) Shijiazhuang; and c) Taicang.
GigaCeuticals Co., Ltd. is aiming at accelerating drug discovery by combining various technologies, including artificial intelligence, systems biology and big data. GigaCeuticals offers prediction, validation and design of small molecule drugs in a multiple purposes fashion against aging related diseases, metabolic diseases and other chronic diseases, which lack of explicit targets or involving a multiple targets mechanism. Currently, the experimentally validated model, at animal level, including extending longevity, anti-obesity, treating hyperuricemia and anti-oxidant / fibrosis.
There are several ways we offer services: i) we predict and validate clients’ self-owned drug-like library using validated model and return top-hit list with experimental reports. ii) We co-develop novel small molecules against certain disease with CRO companies. iii) We sell or license IPs. Other models are under validation including NAFLD/NASH, epilepsy, stem cell renewal, tendon healing, cancer, immunity boost, Alzheimer’s’ disease and etc.
The small molecules we developed has followed properties: i) comparable or better effect than known drugs (first / best-in-class), ii) multiple candidates with similar effects, iii) with multiple purposes, like treating hyperuricemia and anti-fibrosis, iv) with less ADRs. v) continually designing candidates until fulfill all needs, vi) go with novel targets / mechanisms identified.
JenKem Technology is dedicated to the development and supply of PEG-based products and custom PEGylation services, with worldwide distribution, and the recent significant addition of new R&D through commercial scale GMP facilities.
Development and manufacture of a wide range of PEG derivatives with high purity and low polydispersity, currently in 1 gram to 40 kg or greater sized batches, under ISO 9001 and ISO 13485 certified Quality Management Systems, following ICH Q7A guidelines and operating under cGMP protocols for regulated customers. Custom synthesis of Y-Shaped PEGs, Methoxy PEGs, Homobifunctional PEGs, Heterobifunctional PEGs, Multi-arm PEGs, Multi-arm Heterobifunctional PEGs, Monodisperse (Discrete) PEGs, Biodegradable PEG Co-Polymers (such as PEG-PLGA, PEG-PLA, PEG-PCL, and other block polymers), and PEG GPC Standards.
Custom PEGylation of proteins, peptides, oligonucleotides, and small molecules; and conjugation of PEGs to other polymer systems. Large scale manufacturing on a custom synthesis basis, which offers the flexibility to match a customer’s specifications.
Website:www.cas.org
CAS, a division of the American Chemical Society, is dedicated to the ACS vision of improCAS, a division of the American Chemical Society specializing in scientific information solutions, partners with R&D organizations globally to provide actionable insights that help them plan, innovate, protect their innovations, and predict how new markets and opportunities will evolve. Scientific researchers, patent professionals and business leaders around the world rely on our solutions, including SciFindern, STNext®, Formulus®, PatentPak®, MethodsNow® and NCI Global®, to advise discovery and strategy throughout their innovation workflow. CAS also offers custom services that leverage our unique content, technology and expertise to tackle complex information challenges and support the success of digital transformation initiatives. With more than 110 years' experience, no one knows more about scientific information than CAS. Learn more at www.cas.org.
美国化学文摘社(CAS)是美国化学会旗下分支机构专业科学信息提供方,通过与全球研发机构合作,提供切实可行的科学见解,助力规划、创新、保护创新成果,并预测新的市场以及市场机会将如何演变。全球的商业、学术和政府部门的科研人员、专利专家和商业领袖都选择CAS的解决方案和服务(包括SciFindern, STNext®, Formulus®, PatentPak®, MethodsNow® and NCI Global®等),为其发现和战略决策提供建议。CAS无与伦比的内容、专业技术和科学家智慧定制解决方案,为机构带来信息优势。110余年的经验,CAS专注科学信息。更多信息,请访问www.cas.org.
北京海金格医药科技股份有限公司(股票代码:834524)成立于2006年,是一家专注提供临床研究技术服务公司。其主要业务涉及化学创新药临床研究(Ⅰ-Ⅳ期)、生物制品创新药临床研究(Ⅰ-Ⅳ期)、中药及天然药物创新药临床研究(Ⅰ-Ⅳ期)、医疗器械临床研究、生物等效性(BE)及药代动力学(PK/PD)临床研究、化学药一致性评价临床研究、化学仿制药临床研究、中药及化学药注射剂上市后再评价临床研究及学术推广、第三方稽查服务、数据管理与统计分析服务、SMO服务、受试者招募服务、进口药注册服务、特殊医学食品注册及临床研究、临床批件及生产批件技术转让、GCP及法规培训服务、临床研究机构第三方认证培训服务等。
Website: www.e-3.com
E3 was founded by a group of veterans from the pharmaceutical industry determined to solve the serious problems with laboratory safety and energy-efficiency.
The advent of E3's patented breakthrough innovations, the Bernoulli Laminar Air-Curtain Containment Hood and SmartFlow Damper System, has brought forth a solution for the age-long global dilemma of having to compromise between laboratory safety and energy efficiency.
The Bernoulli Hood delivers exceptional "zero-spill" containment safety performance while simultaneous providing unparalleled energy efficiency of up to 80%. With the Bernoulli Hood, laboratory owners can enjoy an unprecedented level of worker safety and HVAC energy cost reduction, drastically reducing their laboratory carbon footprint to achieve an unforeseen level of sustainability.
The Bernoulli SmartFlow Damper System is the most compact and simplified airflow control solution in the world. With an accuracy of over 95% and a response time of less than 2.5 seconds, it is also the first and only product to control airflow through direct real-time measurement of flowrate. Its integrated and patented multi-vane technology eliminates the complexities and costs associated with airflow testing, adjusting and balancing work.
Shanghai Beshining Law Office was founded in 2013 by main partner Xue Qi and his team from Shanghai Zhixin Patent Agent Ltd., and its headquarters is located in Shanghai. As one of the few leading law offices authorized to engage in patent and trademark, we currently house more than one hundred personnel including lawyers, patent attorneys, and other legal and technical professionals with diverse background and expertise. Our partners and their team have been providing nearly thousands of domestic and foreign enterprises with full intellectual property legal service and comprehensive domestic and foreign legal service of patent, trademark, copyright, integrated circuit layout design, anti-unfair competition and trade secret. The quantities of patent applications, trademark applications and lawsuits are all top rated nationwide. Especially, our team in Chemistry, Pharmaceuticals and Biology in which we have 16 lawyers and 36 patent attorneys is in the top tier of China, and our firm enjoys a patent grant rate of over 90% for invention in such areas. For three consecutive years (2015-2017), our team was awarded the title of Outstanding IP Service Team in China by China IP Magazine and China Daily IPR Channel.
LexOrbis is one of the most recommended full service IP firms in India with offices at 3 locations namely, New Delhi, Mumbai and Bangalore. We have a strong team of over 65 attorneys including 46 patent attorneys having expertise in the field of mechanical, electronics, wireless communication, software, mobile applications, chemistry, biotechnology, etc. who are involved in drafting new patent applications originating from India and filing and prosecuting international patent applications. A team of over 19 lawyers at our firm also have deep expertise in handling trademark prosecution and contentious cases. Our patent and trademark attorneys work in combination with our IP litigators to handle a large number contentious IP cases such as pre-and post- grant oppositions, cancellation and infringement suits and criminal enforcement of India rights in India.
Founded in 2011, we provide small molecule process development and manufacturing services to the pharmaceutical industry.
We evaluate our clients needs and provide creative solutions to deliver valuable, enabling compounds from small quantities of unique compounds to support early and pre-clinical development, to large volumes of key intermediates for clinical studies and commercial supply. In addition to all the chemistries you would expect from a world class small molecule developer, we have specialized expertise in developing chiral compounds, unnatural amino acids, and sulphur containing molecules.
Raffles operates 40,000 sq. ft of modern, well-equipped facilities across two sites in Guangdong, and a business development and technical support function in Philadelphia.
Help Stem Cell Innovations is a leading clinical-stage biotechnology company in Nanjing, China, dedicating to the development of next-generation cell-based therapeutics for degenerative diseases. Our first-in-class cell therapy candidates undergoing clinical development utilize human induced pluripotent stem cells (iPSC) generated from our proprietary iPSC platform. By restoring function, these next-generation medicines have the potential to revolutionize current treatment paradigm.
Human iPSC also represents a powerful platform for drug discovery and efficacy evaluation. Assessment of drug safety and efficacy is complex and time consuming. We support our customers by providing high quality, standardized human iPSC-derived cardiomyocytes and neural cells specially designed for drug screening. Together with our customized high-throughput assays, our stem cell products effectively decrease drug attrition rate and costs in drug development processes.
Beijing HFK Bioscience Co. Ltd. (HFK) was founded in 2008 in conjunction with theInstitute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Peking Union Medical College, in Changping District, Beijing, China. HFK is dedicated to developing and providing laboratory animals, animal models for human diseases,laboratory animal diets and related services.HFK's success results from its large group of experienced researchers and innovative elite with its high emphasis on quality. The quality of its products and services is beijing maintained by this large and dedicated research group and consultant team comprised
by international and domestic experts in the field of laboratory animal science. HFK consists of four branches: the Laboratory Animal Resources (LAR), the Laboratory Animal Diets (LAD), the Research and Development (R&D) and Quality Assurance Unit(QAU).
◆The LAR provides more than 1,000,000 SPF rodents annually, including 200 strains of spontaneous and genetically engineered animal models for human diseases.
◆The LAD owns an automated manufacturing system with the capability to produce 5,000 tons of a wide array of high quality diets per year, including specialformulated diets for all kinds of laboratory animal. All diets are in compliance with GLP standards.
◆The R&D offers the service for generating animal models for human diseases,including the surgical, chemical or diet induced, transgenic, gene knock-in or gene knock-out animal models. Cryopreservation and cryorecovery services are alsoavailable.
◆The QAU is independent of other branches, with advanced equipments and a well trained team. The unit is responsible for running the ISO9001 quality management system of the company.
We look forward to working with you to provide you with your basic research needs. We are dedicated to provide you the utmost in quality and price.
Website: www.tzcmc.net
China Medical City (Taizhou National Medical High-tech Zone) is located in Taizhou City, Jiangsu Province. As the first national level life science hi-tech Park, China Medical City (CMC) is jointly built by Ministry of Science and Technology, China Food and Drug Administration (CFDA), National Health and Family Planning Commission, China Administration of Traditional Chinese Medicine and Jiangsu Provincial Government. Jiangsu CFDA CMC Branch, Jiangsu Food and Drug Inspection Institute CMC Branch, Jiangsu Medical Device Testing Center CMC Branch have been established successively to better support the industry and offer services to the companies more efficiently.
We are committed to building the largest life scienceindustrial base with the most integrated industrial chainin China. China Medical City has cooperated with over 50 famous life science R&D institutes domestic and abroad, and there are over 900 companies including AstraZeneca, Boehringer Ingelheim, Nestle, Sanofi-Pasteur, and Takeda in China Medical City.
China Medical City, a new city for life science industryin China, your first choice for investment!
Asia Pharma R&D Leaders Summit 2020  |  Telephone: +86 21 6172 6970  |  E-mail: kevin.tan@deliver-consulting.com
© 2020 Asia Pharma R&D Leaders Summit 2020- All rights reserved